欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的 应用参一胶囊联合放疗治疗Ⅲ、Ⅳ 期非小细胞肺癌（NSCLC）,观察其临床疗效及不良反应。方法 63例Ⅲ、Ⅳ期NSCLC患者按简单随机化方法分为2组,治疗组,35例,给予放疗＋参一胶囊处理;对照组,28例,放疗＋安慰剂处理。比较2组患者的疗效及不良反应。结果 治疗组的近期疗效为57.14%, 显著高于对照组（32.14%,χ2=3.91,P〈0.05）,治疗组的中位生存期为14.2个月,显著长于对照组（11.2个月, χ2=2.07,P〈0.05）,治疗组的1年生存率为62.86%,显著高于对照组（39.29%, χ2=4.40,P〈0.05）;治疗组中各种常见的不良反应（除咳嗽、发热外）发生率,均低于对照组,但两组间差异无统计学意义。结论 参一胶囊联合放疗是治疗晚期NSCLC的有效方法,具有一定的减毒增效作用。
英文摘要：
Objective To study the efficacy and toxicity of gensenoside-Rg3 （Rg3） combined with radiotherapy on non-small cell lung cancer （NSCLC） at advanced stages （Ⅲ and Ⅳ）. Methods Sixty-three patients with stage Ⅲ or ⅣNSCLC were divided randomly into two groups： treatment group （n=35） treated with Rg3 combined with radiotherapy and control group （n=28） treated with radiotherapy alone.The efficacy and side effects were compared after the treatment. Results The response rate （CR＋PR） of the treatment group was 57.14%, significantly higher than that of the control group （32.14%, χ2=3.91, P〈0.05）. The median survival time of the treatment group was 14.2 months, significantly longer than that of the control group （11.2 months, χ2=2.07,P〈0.05）. The one-year survival rate of the treatment group was 62.86%, significantly higher than that of the control group （39.29%, χ2=4.40,P〈0.05）. The incidence rates of side effects of the treatment group were all lower than those of the control group, but there were not significant difference. Conclusions Gensenoside-Rg3 combined with radiotherapy is effective for advanced stage NSCLC, with attenuation and synergistic effects.
同期刊论文项目
同项目期刊论文
期刊信息
位置：